Guidance Summary (as far as it can be extracted from the provided news excerpt):
The press release that announced VolitionRx Limited’s (NYSE American: VNRX) upcoming second‑quarter 2025 earnings conference call mentions that the company will provide guidance for the third quarter of 2025 (Q3 2025) and for the full‑year 2025 during the call.
Specific figures or ranges for Q3 2025 revenue, earnings, cash‑flow, or other performance metrics are **not included in the brief news summary you provided.** The summary only notes the timing of the call (Friday, August 15 at 8:30 a.m. U.S. Eastern Time) and that a “business update” will be given, which will include the Q3 and full‑year outlook.
What can be concluded from the information you have?
| Item | Information available in the summary | What is missing (i.e., the actual guidance) |
|---|---|---|
| Q3 2025 guidance | The conference call will present guidance for Q3 2025. | No numeric guidance (e.g., revenue range, EPS, cash‑flow expectations) is provided. |
| Full‑year 2025 outlook | The call will also present a full‑year outlook. | No numeric guidance (e.g., full‑year revenue, profitability, cash‑flow, or other metric ranges) is provided. |
| Source of the numbers | Not included in the PR‑wire snippet. The detailed press release or the conference call transcript would contain the actual numbers. | – |
How to obtain the exact guidance
- Listen to the conference call (scheduled for Friday, August 15, 8:30 a.m. ET). The call’s transcript or the accompanying slide deck will contain the precise Q3 2025 and full‑year guidance figures.
- Review the full press release (often posted on VolitionRx’s investor‑relations website or the SEC’s EDGAR system). The full release typically contains a “Financial Guidance” section that lists the ranges or specific numbers for Q3 2025 and the full‑year outlook.
- Check subsequent news releases or analyst coverage that may summarize the guidance after the conference call.
Bottom line
Based on the information provided in the PR‑wire excerpt, the actual Q3 2025 and full‑year guidance numbers are not disclosed. To obtain the specific guidance figures, you will need to consult the full press release (or the transcript/slides from the August 15 conference call) where VolitionRx will present those details.